The tropomyosin receptor kinase (Trk) receptor family comprises 3 transmembrane proteins
referred to as Trk A, B and C (TrkA, TrkB and TrkC) receptors that are encoded by the …

Targeted therapies are substantially changing the management of lung cancers. These
treatments include drugs that target driver mutations, those that target presumed important …

Advanced, anaplastic lymphoma kinase (ALK)–positive lung cancer is currently treated with
the first-generation ALK inhibitor crizotinib followed by more potent, second-generation ALK …

Background Despite recent advances in the treatment of advanced non-small-cell lung
cancer, there remains a need for effective treatments for progressive disease. We assessed …

Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …

Background BRAF mutations act as an oncogenic driver via the mitogen-activated protein
kinase (MAPK) pathway in non-small cell lung cancer (NSCLC). BRAF inhibition has shown …

Background The molecular profiling of patients with advanced non-small-cell lung cancer
(NSCLC) for known oncogenic drivers is recommended during routine care. Nationally …

Background We previously found that dual HER2 blockade with trastuzumab and lapatinib
led to inhibition of tumour growth in patient-derived xenografts of HER2-amplified metastatic …

Systematic studies of cancer genomes have provided unprecedented insights into the
molecular nature of cancer. Using this information to guide the development and application …

Background Alectinib—a highly selective, CNS-active, ALK inhibitor—showed promising
clinical activity in crizotinib-naive and crizotinib-resistant patients with ALK-rearranged (ALK …